Related Experiment Video
Updated: Nov 15, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
Synat Kang1, Xuefeng Gao1,2, Li Zhang1
1Department of Hematology and Oncology, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Shenzhen University, Xueyuan AVE 1098, Nanshan District, Shenzhen 518000, Guangdong, China.
Abstract:
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens-matching. Several NK-based therapeutic approaches have been attempted in clinical practice, but their efficacy is not sufficient to suppress tumor development mainly because of lacking specificity. To this end, the engineering of NK cells with T cell receptor along with CD3 subunits (TCR-NK) has been developed to increase the reactivity and recognition specificity of NK cells toward tumor cells. Here, we review recent advances in redirecting NK cells for cancer immunotherapy and discuss the major challenges and future explorations for their clinical applications.
Insights
Engineered Natural Killer (NK) cells with T cell receptors (TCR-NK) show promise for cancer immunotherapy by enhancing tumor cell recognition and reactivity. This review explores advances, challenges, and future directions for TCR-NK cell therapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Natural Killer (NK) cells are crucial for innate immunity and cancer immunotherapy due to their tumor-lysing capabilities without HLA matching.
- Current NK cell therapies face limitations in specificity and efficacy, hindering complete tumor suppression.
- Engineering NK cells aims to overcome these limitations for improved cancer treatment outcomes.
Purpose of the Study:
- To review recent advancements in redirecting NK cells for enhanced cancer immunotherapy.
- To discuss the development of T cell receptor-engineered NK (TCR-NK) cells for improved tumor recognition.
- To explore the challenges and future prospects of TCR-NK cell clinical applications.
Main Methods:
- Review of current literature on NK cell-based cancer immunotherapies.
- Focus on engineering strategies, specifically the incorporation of T cell receptor and CD3 subunits into NK cells (TCR-NK).
- Analysis of studies demonstrating enhanced NK cell reactivity and specificity towards tumor targets.
Main Results:
- TCR-NK cell engineering significantly increases NK cell reactivity and specificity against tumor cells.
- This approach addresses the limitations of traditional NK cell therapies regarding tumor recognition.
- Engineered NK cells demonstrate potential for more effective cancer immunotherapy.
Conclusions:
- TCR-NK cell technology represents a promising strategy to enhance NK cell-based cancer immunotherapy.
- Further research and clinical exploration are needed to overcome challenges and optimize TCR-NK cell therapy.
- Redirected NK cells hold significant potential for future cancer treatment modalities.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...